SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-17-000045
Filing Date
2017-04-25
Accepted
2017-04-25 16:29:55
Documents
4
Period of Report
2017-04-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a8-karecla.htm 8-K 41301
2 EXHIBIT 99.1 pressrelease-april252017.htm EX-99.1 27213
3 ctilogoa24.jpg GRAPHIC 4570
4 pressreleaseapril2420_image2.gif GRAPHIC 4747
  Complete submission text file 0000891293-17-000045.txt   82891
Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 17781415
SIC: 2834 Pharmaceutical Preparations